文献速递骨质疏松与代谢性骨病

现代雌激素治疗骨质疏松症

Estrogen therapy for osteoporosis in the modern era.
PubMed 文献 · Osteoporos Int · 2018-03-08

本文综述雌激素治疗(HT)用于骨质疏松症预防与治疗的研究证据。妇女健康倡议(WHI)随机对照试验首次证实HT降低绝经后女性所有骨质疏松相关骨折发生率,但认为不良反应超过骨骼潜在获益。后续研究显示HT可改善骨密度并降低骨折风险,低剂量与经皮HT与乳腺癌、子宫内膜增生、冠心病和静脉血栓栓塞症的不良反应关联较少。作者提出在合适人群中可考虑HT用于骨质疏松症的一级预防和治疗。

要点

  • WHI随机对照试验首次证实HT降低绝经后女性所有骨质疏松相关骨折的发生率。
  • 后续研究显示HT改善骨密度并降低骨折风险,低剂量与经皮HT的不良反应关联较少。
  • 作者认为在合适人群中可考虑HT用于骨质疏松症的一级预防和治疗。

核心结论

  • 作者认为,鉴于绝经后女性对雌激素的需求以及支持HT成本效益、安全性和有效性的证据,可考虑在合适人群中用HT进行骨质疏松症的一级预防和治疗。
  • 作者认为,HT应个体化,不应再使用「最低剂量、最短时间」的概念。

研究设计与样本

  • 本文为综述,聚焦既往和当前关于各种HT制剂用于骨质疏松症预防和治疗的研究。

主要发现

  • WHI随机对照试验首次证实HT降低绝经后女性所有骨质疏松相关骨折的发生率,但该研究认为不良反应超过对骨骼的潜在获益。
  • 后续研究显示,HT在不同剂量、疗程、方案和给药途径下均具有显著疗效,可改善骨密度并降低骨折风险,无论女性是否患有骨质疏松症。
  • 研究提示,低剂量和经皮HT与乳腺癌、子宫内膜增生、冠心病(CAD)和静脉血栓栓塞症(VTE)的不良反应关联较少,这些不良反应此前在标准剂量口服HT方案中观察到。

临床怎么用

  • 作者认为,在合适人群中可考虑HT用于骨质疏松症的一级预防和治疗。
  • 作者认为,HT应个体化,不应再使用「最低剂量、最短时间」的概念。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Menopause predisposes women to osteoporosis due to declining estrogen levels. This results in a decrease in bone mineral density (BMD) and an increase in fractures. Osteoporotic fractures lead to substantial morbidity and mortality, and are considered one of the largest public health priorities by the World Health Organization (WHO). It is therefore essential for menopausal women to receive appropriate guidance for the prevention and management of osteoporosis. The Women's Health Initiative (WHI) randomized controlled trial first proved hormonal therapy (HT) reduces the incidence of all osteoporosis-related fractures in postmenopausal women. However, the study concluded that the adverse effects outweighed the potential benefits on bone, leading to a significant decrease in HT use for menopausal symptoms. Additionally, HT was not used as first-line therapy for osteoporosis and fractures. Subsequent studies have challenged these initial conclusions and have shown significant efficacy of HT in various doses, durations, regimens, and routes of administration. These studies support that HT improves BMD and reduces fracture risk in women with and without osteoporosis. Furthermore, the studies suggest that low-dose and transdermal HT are less likely associated with the adverse effects of breast cancer, endometrial hyperplasia, coronary artery disease (CAD), and venous thromboembolism (VTE) previously observed in standard-dose oral HT regimens. Given the need for estrogen in menopausal women and evidence supporting the cost effectiveness, safety, and efficacy of HT, we propose that HT should be considered for the primary prevention and treatment of osteoporosis in appropriate candidates. HT should be individualized and the once "lowest dose for shortest period of time" concept should no longer be used. This review will focus on the prior and current studies for various HT formulations used for the prevention and treatment of osteoporosis, exploring the safety profile of low-dose and transdermal HT that have been shown to be safer than oral standard-dose HT.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Levin VA, Jiang X, Kagan R, et al. Estrogen therapy for osteoporosis in the modern era. Osteoporos Int. 2018. PMID: 29520604. doi:10.1007/s00198-018-4414-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。